潘生丁增强氨甲蝶呤的抗肿瘤作用

外源性核苷能抵消抗代谢药对肿瘤细胞的杀伤作用;核苷转运抑制剂潘生丁则能阻断核苷的这种抵消作用,从而增强抗代谢药的细胞毒性。本研究证明,胸苷和次黄嘌呤可明显抵消氨甲蝶呤对L1210细胞的杀伤作用,潘生丁则能有效地阻断核苷的抵消作用;潘生丁和两性霉素B合用可明显增强氨甲蝶呤对小鼠S180肉瘤的抑制作用,但不增强氨甲蝶呤对动物的毒性。提示潘生丁有可能应用于肿瘤联合化疗。     

Potency variation of small-molecule chymase inhibitors across species

Chymases (EC 3.4.21.39) are mast cell serine proteinases that are variably expressed in different species and, in most cases, display either chymotryptic or elastolytic substrate specificity. Given that chymase inhibitors have emerged as potential therapeutic agents for treating various inflammatory, allergic, and cardiovascular disorders, it is important to understand interspecies differences of the enzymes as well as the behavior of inhibitors with them. We have expressed chymases from humans, macaques, dogs, sheep (MCP2 and MCP3), guinea pigs, and hamsters (HAM1 and HAM2) in baculovirus-infected insect cells. The enzymes were purified and characterized with kinetic constants by using chromogenic substrates. We evaluated in vitro the potency of five nonpeptide inhibitors, originally targeted against human chymase. The inhibitors exhibited remarkable cross-species variation of sensitivity, with the greatest potency observed against human and macaque chymases, with K_i values ranging from ∼0.4 to 72 nM. Compounds were 10-300-fold less potent, and in some instances ineffective, against chymases from the other species. The X-ray structure of one of the potent phosphinate inhibitors, JNJ-18054478, complexed with human chymase was solved at 1.8 Å resolution to further understand the binding mode. Subtle variations in the residues in the active site that are already known to influence chymase substrate specificity can also strongly affect the compound potency. The results are discussed in the context of selecting a suitable animal model to study compounds ultimately targeted for human chymase.     

中草药醛糖还原酶抑制剂筛选模型的建立

目的：通过观察中药知母对醛糖还原酶活性的抑制作用，建立一种适用于筛选中草药醛糖还原酶抑制剂的模型。方法：大鼠12只随机分成3组：空白对照组、知母组、阳性药物组，分别给予生理盐水、知母水提液、依帕司他水溶液灌胃。采用“通法”给药方案制备含药血清，部分血清经过丙酮预处理。将知母水提液和含药（知母）血清分别加人体外建立的以DL-甘油醛为底物、NADPH为辅酶的醛糖还原酶活性测定体系。结果：丙酮处理过的空白血清较未处理的空白血清对酶活性的影响更小；知母水提液对醛糖还原酶抑制率达99％，含药（知母）血清对醛糖还原酶抑制率达67％。结论：运用血清药理学实验方法建立的筛选模型能有效、可靠的进行中草药醛糖还原酶抑制剂的筛选。     

血管性血友病因子及其裂解酶在肺癌患者中的表达及其意义

目的探讨肺癌患者在不同病理状态下血管性血友病因子(vWF)水平及其裂解酶(vWF-cp)活性的改变及临床意义。方法以残余胶原结合实验及ELISA分别测定2003年10月至2005年1月苏州大学附属第一医院呼吸科78例肺癌血浆vWF-cp和vWF,对其中23例合并胸腔积液的肺癌患者以放免法测定血清和胸水癌胚抗原(CEA)水平。结果(1)肺癌患者vWF抗原(vWFAg)(107.7±43.7)%显著高于正常对照组(71.3±49.5)%及肺良性疾病组(82.4±41.3)%(P<0.05),而vWF-cp活性水平在肺癌患者(59.2±21.5)%显著低于正常对照组(86.6±1.8)%和肺良性疾病组(79.4±13.3)%(P<0.05);二者在肺癌晚期广泛转移较局限期差异均有显著性;(2)血浆vWFAg与胸水CEA呈正相关,而vWF-cp与胸水CEA呈负相关。结论肺癌患者血浆vWFAg升高、vWF-cp降低,并与疾病进展有关。     

脊髓损伤后热休克蛋白27、表皮脂肪酸结合蛋白和金属蛋白酶组织抑制因子-1的基因表达及甲基强的松龙对其表达的影响

目的研究脊髓损伤后热休克蛋白27(HSP27)、表皮脂肪酸结合蛋白(FABPs)和金属蛋白酶组织抑制因子-1(TIMP-1)的基因表达及甲基强的松龙(MP)对其表达的影响.方法SD大鼠30只.随机分为假手术组、单纯脊髓损伤组(损伤组)及脊髓损伤+大剂量MP治疗组(MP组),每组10只.应用改良的Allen's打击法致T8脊髓损伤.MP组大鼠伤后即刻从尾静脉内注射大剂量MP(30mg/kg).损伤后24h切取损伤平面上下0.5cm的脊髓组织,进行RT-PCR反应,检测HSP27、FABPs和TIMP-1的基因表达.结果术后24h假手术组HSP27、FABPs和TIMP-1的基因表达相对丰度分别为0.0643±0.0152、0.6413±0.1005和0.7091±0.0577;损伤组上述三个因子的表达升高,分别为1.0013±0.3861、1.2187±0.2851和0.8971±0.1092,与假手术组比较差异有显著性(P＜0.01、P＜0.05、P＜0.05);MP组上述三个因子的表达继续升高,分别为1.2858±0.1384、1.7122±0.1766和1.2081±0.1093,与损伤组比较差异有显著性(P＜0.05、P＜0.01和P＜0.01).结论脊髓损伤后,邻近损伤处的脊髓组织中HSP27、FABPs及TIMP-1的基因表达显著增高,大剂量MP能进一步促进三个因子表达,发挥组织保护作用.     

Proteasome Inhibitors Sensitize Hepatocellular Carcinoma Cells to TRAIL

A poptosis, an evolutionarily conserved form of cell suicide, oc- curs in two physiological stages: commitment and execution.[1] It has been found that several Bcl-2 family proteins are located in the outer mitochondrial membrane, where they control relea…     

Effect of naringin on bone cells.

Statin, a HMG-CoA reductase inhibitor, was shown to increase BMP-2 gene expression for bone formation, by blocking the mevalonate pathway in cholesterol production. We investigated the effect of naringin, a flavonoid available commonly in citrus fruits, which was also a HMG-CoA reductase inhibitor, in UMR 106 osteoblastic cell line in vitro. The control group consisted of cells cultured without any intervention for different time intervals (24 h, 48 h, and 72 h), whereas the experimental (naringin) group consisted of cells cultured with naringin of different concentrations (0.001 micromol/L, 0.01 micromol/L, and 0.1 micromol/L) for the same time intervals of the control. Colorimetric Tetrazolium (MTT) assay, total protein content assay, and alkaline phosphatase activity were used to measure the cellular activities. Results for the naringin group showed an increase in MTT assay compared with the control and the effect was dose dependent. At high concentration (0.1 micromol), the increases ranged from 60% to 80%. In the total protein content assay, naringin also showed an increase compared with control and the effect was also dose dependent. At high concentration (0.1 micromol), the increases ranged from 9% to 20%. In the alkaline phosphatase activity assay, naringin at high concentration (0.1 micromol) significantly increased the activity up to 20%. In conclusion, naringin significantly increased bone cell activities in vitro. This is the first study specifically attempted to investigate the effect of naringin on bone cell activities. Besides statin, this provided another example of mevalonate pathway blockage in the cholesterol production pathway by HMG-CoA reductase inhibition will increase the bone cell activities.     

酪氨酸激酶抑制剂对气管上皮细胞生长的影响

目的探讨酪氨酸激酶抑制剂(Tyrosine kinase inhibitor,TKI)对培养气管上皮细胞生长的影响.方法通过MMT法、3H-胸腺嘧啶(3H-TdR)掺入法及流式细胞计数,观察3种TKIs:Tyrphostin AG1478、Genistein(Sigma)及金转停对原代培养的大鼠气管上皮细胞增殖、周期及凋亡的影响,以及TKIs对表皮生长因子(EGF)的阻断作用.结果MTT法显示3种TKI均对气管上皮细胞的生长具有时间和剂量依赖性抑制作用,同时,TKI阻断EGF对气管上皮细胞生长的刺激作用,3种TKIs的作用无明显差异;1μmol/L的Tyrphostin AG1478、Genistein及金转停分别使气管上皮细胞的TdR掺入率降低18.3%、20.9%及19.7%,与MTT比色法结果一致.同时,Tyrphostin AG1478不仅加速气管上皮细胞的凋亡而且阻止细胞有丝分裂.TKIs可阻断表皮生长因子(EGF)对气管上皮细胞生长的刺激作用.结论TKIs不仅抑制对原代培养的大鼠气管上皮细胞的生长,加速其凋亡,而且可阻断EGF对气管上皮细胞生长的刺激作用,3种抑制剂的作用无明显差异.     

Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin® SDH in previously treated patients with severe haemophilia A

Clinical efficacy, safety and pharmacokinetic properties of the high-purity double-virus inactivated plasma-derived factor VIII concentrate Haemoctin SDH (pdFVIII) were evaluated in three prospective open-label uncontrolled studies in previously treated patients (PTPs) with severe haemophilia A. The pharmacokinetic properties assessed at baseline and after 3 months of treatment are in accurate accordance with published data and remain unchanged over time (study A, n = 12). Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively. Long-term efficacy and safety, in particular the potential immunogenicity, were investigated in a total of 53 PTPs (studies A and B) treated prophylactically and on-demand, as required. PdFVIII has shown to be effective in preventing and controlling bleeding episodes; 23.5% of patients were free of bleeding events. A total of 177 haemorrhages occurred with 74.0% resolving after a single infusion, 87.6% within two infusions. 98.3% of responses reported on haemorrhages were rated as 'excellent' or 'good'. Moreover, 'excellent' haemostatic efficacy has been demonstrated in 10 surgical procedures including general and severe orthopaedic interventions (study C). No complication occurred in any surgery. Few adverse events were reported, one patient developed a high-titre FVIII inhibitor without clinical relevance. In all three studies, over 6 million units were administered in nearly 4300 infusions, approximately 94% units or infusions were given for prophylaxis and only 6% for treatment on-demand. In conclusion, pdFVIII has shown to be effective, safe and well tolerated in long-term prophylaxis and treatment on-demand as well as after minor and major surgical procedures.